Institutional members access full text with Ovid®

Share this article on:

Fingolimod-Associated Intracerebral Lymphoproliferative Disorder

Baharnoori Moogeh MD PhD; Mahajan, Rahul MD; Solomon, Issac H. MD, PhD; Pinkus, Geraldine MD; Houtchens, Maria MD
American Journal of Therapeutics: Post Author Corrections: October 27, 2017
doi: 10.1097/MJT.0000000000000694
Therapeutic Challenge: PDF Only

Most epidemiological studies indicate that incidence of cancer in multiple sclerosis patients is lower than general population. However these studies were performed prior to the emergence of disease-modifying therapies (DMTs). The incidence of cancer may be influenced by newer generation DMTs which are immunomodulatory or immunosuppressant. We describe an atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod. As worldwide usage of oral and infusion DMTs increases, heightened clinical suspicion and early recognition of these serious adverse events remain crucial.

Address for correspondence: Partners Multiple Sclerosis Center, 60 Fenwood Road, Building for Transformative Medicine, Boston, MA 02115-6128. E-mail: mhoutchens@BWH.harvard.edu

The authors have no conflicts of interest to declare.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.